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Abstract
Background: Congenital dilatation of the bile-duct (CDD) is a rare, mostly sporadic, disorder that results in bile
retention with severe associated complications. CDD affects mainly Asians. To our knowledge, no genetic study
has ever been conducted.
Methods: We aim to identify genetic risk factors by a “trio-based” exome-sequencing approach, whereby 31 CDD
probands and their unaffected parents were exome-sequenced. Seven-hundred controls from the local population
were used to detect gene-sets significantly enriched with rare variants in CDD patients.
Results: Twenty-one predicted damaging de novo variants (DNVs; 4 protein truncating and 17 missense) were
identified in several evolutionarily constrained genes (p < 0.01). Six genes carrying DNVs were associated with human
developmental disorders involving epithelial, connective or bone morphologies (PXDN, RTEL1, ANKRD11, MAP2K1, CYLD,
ACAN) and four linked with cholangio- and hepatocellular carcinomas (PIK3CA, TLN1 CYLD, MAP2K1). Importantly, CDD
patients have an excess of DNVs in cancer-related genes (p < 0.025). Thirteen genes were recurrently mutated at
different sites, forming compound heterozygotes or functionally related complexes within patients.
Conclusions: Our data supports a strong genetic basis for CDD and show that CDD is not only genetically
heterogeneous but also non-monogenic, requiring mutations in more than one genes for the disease to develop.
The data is consistent with the rarity and sporadic presentation of CDD.
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Background
Congenital dilatation of the bile ducts (choledochal cyst/
CDD) result in bile retention, with cholangitis, pancreatitis
and malignancies as associated complications. The main
symptoms are cholestatic jaundice, abdominal pain and
liver enlargement. If the obstruction is not relieved the
liver can be permanently damaged [1, 2]. Surgery is the
only available treatment. CDD is a rare, mostly sporadic,
disorder whose incidence varies widely among populations
(from 1 in 1,000 in Asians to 1 in 150,000 in Caucasians).
CDD is anatomically classified in 5 major types (I-V) [3].
Types I and IV denote dilatation of the common biliary
duct (CBD) without (type I) or with (type IV) dilated
intrahepatic ducts and are the commonest, representing
50%–80% and 15%–35% of the CDD paediatric popula-
tion, respectively. Type II CCDs appear as a diverticulum
protruding from the wall of the CBD and Type III as a
dilatation of the duodenal portion of the CBD. Type V or
Caroli disease, refers to a congenital polycystic dilatation
only affecting intra hepatic biliary ducts. Type V is con-
sidered as a distinct entity as, unlike the other types, is
usually associated with both cystic renal disease and liver
fibrosis (Caroli syndrome).
There are two main theories on the aetiology of Types
I and IV CDD, the “obstructing segment” hypothesis and
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the “pancreatic reflux” hypothesis. The former suggests
that a congenital stenosis of the distal bile duct increases
the intralumenal pressure which, in turn, dilates the
proximal part of the choledoch. The latter proposes that
CDD is caused by reflux of pancreatic enzymes into the
CBD as a result of an anomaly of the pancreaticobiliary
junction. Mixing and activation of the pancreatic and
biliary secretions deteriorate the CBD wall and lead to
dilatation [4, 5].
Both theories imply the presence of congenital struc-
tural anomalies that are likely to reflect a failure in the
hepatobiliary-pancreatic development during embryonic
stages. Although familial cases of CDD have been re-
ported [6], the overall evidence for a classic genetic in-
heritance of the phenotype is scant. Nonetheless the, i)
the female/male bias observed for Types I and IV CDD;
ii) the marked difference in incidence among popula-
tions; iii) the rarity of the disorder together; iv) the pres-
ence of congenital structural anomalies; and the fact that
CDD types I or V can be associated with familial aden-
omatous polyposis [7] and autosomal recessive or dom-
inant polycystic kidney disease (PKD) respectively [8],
are strong indicators of a genetic contribution to CDD.
Yet the scarcity of pedigrees segregating the disorder
and the rarity of the disease make identification of
genetic risk loci by traditional study designs difficult.
Conceivably, DNA alterations in genes governing the
embryonic development of the hepatobiliary-pancreatic
system could underlie CDD.
Given all of the above, we set out to investigate the gen-
etic basis of CDD under the hypothesis that rare de novo
or recessive inherited damaging genetic variants could trig-
ger the disorder and account the sporadic presentation of
CDD, the scarcity of familial cases and the variability in its
incidence across populations. For the identification of loci
underlying “sporadic” (no family history) genetic disorders,
the best strategy is the trio-based approach whereby the ex-
ome of unaffected parents and affected probans is scruti-
nized [9]. Known DNA-variants are filtered out leaving
researchers with DNA-variants/mutations unique to the
trio (both de novo and inherited). Parents/child filtering is
used to identify de novo mutations.
Methods
Study design
We adopted the “trio-based” whole exome-sequencing
approach by which the exomes of the patient and his/
her unaffected parents are analysed.
Common DNA-variants were filtered out leaving only
variants whose minor allele frequency (MAF) in the gen-
eral population is < =1%. This is consistent with recessive
transmission of the disorder and in line with its incidence
in Asia (Additional file 1). Comparison of parental and
offspring sequence was used to identify de novo variants.
The study was approved by the institutional review
board of The University of Hong Kong together with the
Hospital Authority (IRB: UW 07–321). Blood samples
were drawn from all participants after obtaining in-
formed consent (parental consent in new-borns and
children below age 7) and experiments were carried out
in accordance with the approved guidelines.
Patients
A total of 33 CDD ethnic Chinese patients (1 male and
32 females) with dilatation of the common biliary duct
and their parents were included in the study. Patients
from Hong Kong (N = 25 trios; 1 male and 24 females)
were recruited through our specialist clinic to which all
patients in the territory are referred. Eight additional
ethnic Chinese trios (8 females) were recruited through
the National Hospital of Pediatrics in Hanoi, Vietnam.
Patients were diagnosed antenatally, by ultrasound, or
postnatally by magnetic resonance cholangiopancreato-
graphy (MRCP). Clinical characteristics of the patients
are detailed in Additional file 1: Table S1.
Controls
For association tests and quality assessment, data from
700 local Chinese participating in a degenerative disc
disease (DDD) in-house exome sequencing project were
added to the calling set (Additional file 1).
Procedures
Whole Exome Sequencing (WES) and bioinformatics
analyses
Additional file 1.
Testing enrichment of genes mapped on significantly
mutated regions (SMRs) in cancers
A recent study has summarized significantly mutated re-
gions (SMRs) in 21 types of cancer [10]. These mutated
regions overlap among different type of cancers and pro-
vide insights into the molecular mechanisms underlying
tumorigenesis. To identify susceptibility genes shared by
cancer and CDD, we tested our samples for enrichment
of de novo mutated SMR genes. A total of 610 SMR
genes listed on the paper were retrieved and the test was
performed by hypergeometric test.
Tests on inherited variants: homozygosis, compound and
di-genic heterozygosity
We hypothesised monogenic and digenic recessive inherit-
ance models for the disease. We considered the following
i) homozygous variations; ii) compound heterozygous
(CH), and iii) variants in two different but interacting
genes (PPIs). For each scenario, we only considered vari-
ants inherited from different parents, that is, we required
both maternal and paternal rare alleles, which would fit
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the mostly sporadic presentation of CDD. Since rare vari-
ants are more likely to cause disease, allele frequency was
restricted to < =1% MAF giving an incidence for any such
combination in an individual of < =0.01%.
However gene length would affect how many of these
rare mutations might be seen in the parents in a given
gene, as would population specific linkage disequilib-
rium. To account for these two issues and to calculate
the genetic burden of each CH or PPI event in patients
we performed case–control association tests whereby
the co-occurrence of two variants per individual were
compared.
For CH and homozygous events, we tested the burden
of genes containing > =2 damaging variants on each sin-
gle individual using Fisher exact test. CH and homozy-
gous events with p-values >0.01 were removed.
For PPI interacting pairs with a rare variant each, we
filtered out those PPI pairs with p-values >0.01 in their
respective set-based analysis (described above). To further
narrow down our results, only recurrent PPI events were
included in these tests.
Gene based and set based association tests
Enrichment tests on rare damaging variants were per-
formed at gene level. A Kernel style association test, the
Sequence Kernel Association Test (SKAT) [11] was
chosen for the purpose. The test was carried out by the
program RVTEST (rare variant test software for next gen-
eration sequencing data), which implements the SKAT
test and accepts gene-based as well as set based tests (PPI
-protein-protein interactions- and pathways) as options.
Only SNVs with MAF < = 1% in the 1000 Genome project,
ESP6500 and dbSNP137 databases were included. The
same criterion was applied to SNVs of our in-house ex-
ome dataset (exomes of 700 Chinese individuals).
To check the association results for batch bias, controls
(N = 700) were compared with pseudo-controls (N = 52)
derived from other trio-based in-house sequencing study.
These pseudocontrols had been sequenced in the same
batch and processed using the same analysis pipeline as
our cases. Since the pseudocontrols also represent the
normal population, SNVs overrepresented in any of the
groups being compared (controls vs. pseudocontrol) were
indicative of batch bias and were therefore removed from
the call set.
For gene-based association tests, genes carrying 3 or fewer
variants were excluded from the analysis. The removal of
genes with insufficient markers can increase power by redu-
cing the number of multiple testing corrections.
For set-based association tests, we considered groups
of genes with similar biological functions as the unit of
testing. In these tests, we used multiple sources of bio-
logical knowledge including protein-protein interactions
(PPI) and curated pathways. Gene-sets linked by PPI
were retrieved from STRING v9.5 database [12]. Only
PPI pairs with medium experimental evidence or above
(threshold of 0.4 according to STRINGDB website) were
used. Genes carrying filtered SNVs were used to produce
these PPI pairs, we included only PPI-sets with 5 or
more markers in the tested sets.
Pathway sets for testing were retrieved from MSigDB,
KEGG, Biocarta and REACTOME. Similar to the PPI
based analyses, we included only gene-sets with 5 or
more markers in each test. In total there were ~9000
PPI pairs and 1056 pathways being tested by SKAT,
resulting p-values were corrected by the number of PPI/
Pathway sets tested.
Results
Sample processing
We conducted a whole exome sequencing (WES) analysis
of 33 CDD trios to identify causal genetic variations within
coding regions. All patients had a normal karyotype.
There is a remarkable difference of sex ratio in our
sample set (female:male = 32:1). This ratio does not re-
flect that of our population [2, 13] but the selection
process of the patients included in the study which was
dependent on the availability of parental DNA (trios)
and willingness to participate.
Two trios were excluded from the analysis due to DNA
contamination and non-maternity relationship, respect-
ively. Thus, 31 trios were analysed.
Analysis
As pathological mechanisms we considered the effect of
damaging de novo germ-line mutations and rare recessive
inherited variants in i) homozygosis; ii) compound hetero-
zygosis (CH; different mutations in the same gene, one pa-
ternally and one maternally inherited and iii) a “di-genic
model” assuming that variants in different genes of related
pathways coexist in the patient through maternal and pater-
nal inheritance. The combined effect of several variants (ei-
ther de novo + inherited or inherited) was also considered.
We also performed case–control association tests to
capture the possible enrichment of rare variants in a given
gene in the patients. Gene-based and, the more powerful,
gene-set/pathway-based tests were carried out to identify
genes with damaging alleles that, alone or together with
their interacting partners, are associated with CDD.
In total, predicted damaging variants were found in 34
genes, and these were distributed among 23 trios. In the
remaining 8 trios no damaging variants were identified
(Additional file 1: Table S2).
De novo variants
We have identified 27 non-synonymous de novo variants
among 31 trios through our pipeline, 24 of them were val-
idated by Sanger sequencing, achieving an 89% validation
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rate. Among the validated de novo variants, 21 were pre-
dicted damaging (4 protein truncating and 17 missense
mutations) and mapped to the coding sequences (CDS) of
21 genes of 19 CDD patients (Table 1). The de novo dam-
aging CDS variant rate is 0.6 per patient and that of the
overall de novo CDS mutations (damaging and not dam-
aging) is 1.1 per patient. The non-synonymous to syn-
onymous ratio (NS:S) of de novo variants is 3:1 which is
comparable to a reported random model (NS:S = 2.85:1)
[14] and slightly higher than the ratio reported by 1000
Genomes Project (NS:S = 1.14:1) [15].
Non-synonymous de novo variants were annotated
(Table 1) and their Constraint Scores [16] (Additional file
1: Table S2) calculated (Fig. 1). The plot shows that the
gene constraint scores deviate from the empirical normal
distribution to a bimodal distribution with a set of 4 genes
being evolutionary constrained (constrain score cut-off =
3.09, corresponding to P < 0.001). The average constraint
score of 21 damaging de novo variants is significantly
higher than that obtained randomly (empirical p < 0.01
using random sampling without replacement). This means
that changes on those genes are less tolerated hence, more
likely to cause disease [16].
We then queried the Clinical Variation (ClinVar) database
[17] to assess the involvement of the 21 CDD genes carry-
ing de novo variants in other human disorders. Six out the
21 genes are involved in human genetic diseases –mostly
developmental-(PXDN, RTEL1, ANKRD11, MAP2K1, CY
LD and ACAN) where epithelial, connective or bone
morphologies being a common denominator (Additional
file 1: Table S2). Protein truncating variants were detected
for PXDN, RTEL1, ANKRD11 and PPP2R2B. Importantly a
damaging inherited mutation was also detected in the de
novo mutated TXLNB gene.
CDD patients with mutations in genes known to be in-
volved in other congenital human disorders were clinically
re-assessed. Except for patient CC4C (MAP2K1 damaging
variant), in whom some developmental delay features had
already been observed, none of the CDD patients showed
signs of the disorders attributed to the genes in which they
Table 1 List of de novo damaging variants
Family Genes Variant type Protein change DNA Change Associated human disease Mouse phenotypea
CC14 PQLC2 M p.V2F c.4G > T NA NA
CC205 PTGER3 M p.A158V c.473C > T NA NA
CC226 ACAN M p.C2282R c.6844 T > C Spondyloepimetaphyseal
dysplasia (AR), Osteochondritis
dissecans
Abnormal liver morphology,
enlarged liver
CC234 KRT80 M p.S249C c.745A > T NA NA
CC3 TENM4 M p.R2238W c.6712C > T NA NA
CC35 TMEFF1 M p.H231R c.692A > G NA NA
PXDN F p.P225fs c.673delC Sclerocornea (AD) NA
CC4 MAP2K1 M p.I103S c.308 T > G Noonan's syndrome (AD, AR) NA
CC55 ANKRD11 M p.K1464fs c.4388del-GAGA KBG syndrome (AD) NA
TLN1 M p.R2398W c.7192C > T NA NA
CC7 PPP2R2B F p.G386fs c.1128del-G Spinocerebellar ataxia (AD) NA
CC81 C6 M p.W571C c.1713G > T Complement component 6 deficiency NA
HEATR6 M p.T948I c.2843C > T NA NA
PIK3CA M p.I191M c.573A > G Keratosis seborrheic (AD), cancer Increased pancreatic beta
cell number
VC10 PPP1R15B M p.P139H c.416C > A NA Abnormal liver morphology
RTEL1 S p.G973b c.2917G > T Dyskeratosis congenital (AR/AD),
Pulmonary fibrosis (AR)
NA
TXLNB M p.R211Q c.632G > A NA NA
VC61 CYLD M p.W487L c.1460G > T Familial multiple trichoepitheliomata;
Spiegler-Brooke syndrome (AR)
Abnormal intestinal
epithelium morphology
KCNH3 M p.V195A c.584T > C NA NA
SDC3 M p.R302W c.904C > T NA NA
VC63 ZNF330 M p.F54L c.160T > C NA NA
AR autosomal recessive, AD autosomal dominant, M missense, S stopgain, F frameshift, NA not described
ahepatobiliary/pancreas
bHGVS standard for stop-codons
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had damaging de novo variants. Importantly, the finding of
a MAP2K1 (Noonan's syndrome [18, 19]) damaging variant
(c. 308 T >G, p.I103S) in patient CC4D helped confirm the
diagnosis of the patient with Noonan's syndrome. CDD and
keratosis pilaris (skin disorder) have also been reported in
several Noonan’s syndrome patients [20–22].
Five genes with de novo damaging alleles PIK3CA,
TLN1 CYLD, and MAP2K1, are linked with cholangio-
and hepatocellular carcinomas in addition to congenital
syndromes and conditions related to tissue overgrowth
[23–26]. It is worth remarking that people affected with
Brooke-Spiegler syndrome or familial cylindromatosis
are born with one damaging allele in CYLD but a second
damaging variant (somatic) needs to occur in the epithe-
lial tissues for the disease to manifest, a process reminis-
cent of cancer development.
Genes carrying de novo variants enriched in significantly
mutated regions (SMRs) in cancers
A recent study has summarized significantly mutated re-
gions (SMRs) in 21 types of cancer [10]. In total, these
regions comprise 610 genes thought to carry the “driver”
mutations in different types of cancers. We found that
de novo variants in SMR genes were in excess in our
dataset (enrichment test p < 0.0249). This enrichment
was due to the de novo variants in PIK3CA, C6 and
PPP2R2B. PIK3CA was highlighted by its very high
density of mutations affecting 9 types of cancers, sug-
gesting its key role in cancer development.
Inherited variants: homozygous, compound homozygous
and di-genic models
We then assessed the patients for inherited damaging
variants acting in a recessive manner. To identify com-
pound heterozygotes (CH) we performed a gene burden
test whereby those CH with p < 0.01 present in more
than one patient (recurrently mutated) were considered.
CH recurrent events with at least one damaging allele
were identified for 4 genes (DCHS1, C5orf42, TXLNB and,
PRRC2A) and distributed among 7 families (Additional file
1: Table S2). As above, we queried the ClinVar database.
DCHS1 was found to have 4 different alleles forming two
different CH in two different families (CC205 and VC84).
In spite of DCHS1 being linked to Van Maldergem Wetz-
burger Verloes syndrome, an autosomal recessive disorder
characterized by intellectual disability, typical craniofacial
features, auditory malformations resulting in hearing loss,
and skeletal and limb malformations, neither patient had
any sign of that syndrome. DCHS1 is a key member of the
planar cell polarity pathway which is involved in the regu-
lation of the cytoskeleton that shapes the cells during
mammalian development. Similarly, C5orf42 was also
found to have 4 different alleles forming two different CH
in two different families (CC35 and CC9). This gene is as-
sociated with several developmental delay disorders in-
cluding some forms of the autosomal recessive Joubert
syndrome, global developmental delay and with the auto-
somal recessive orofaciodigital syndrome VI (polydactyly,
cleft lip/palate or lingual lump, and psychomotor retard-
ation). Neither TXLNB nor PRRC2A is linked to any hu-
man disease. TXLNB was also de novo mutated in patient
VC10 and a homozygous PRRC2Amutation was identified
in patient CC98.
Similar to the filtering strategy adopted for CH events,
both recurrence and burden were considered for PPI pairs.
After filtering, a total of 5 PPI combinations (KRT18 +
BYSL, THBS1 +COL7A1, TP53 + SETD8, EPS15 +DNM1,
and POU2F2 + PGR) distributed among 10 families were
detected. All these genes are known to play pivotal roles in
development.
Fig. 1 Distribution of constraint scores of all genes with de novo non-synonymous variants. Y axis: number of genes whose constrain scores fall
into the range specified in the X axis. X axis: constrain scores as defined by Samocha et al. [16]. (The genes with constraint score > 3.09 are highly
constrained, corresponding to P < 0.001 and represented roughly 5% of all genes.)
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KRT18 encodes a protein for making structural keratin
in hepatocytes. KRT18 mutations cause infantile liver cir-
rhosis. Krt18 mutant mice develop chronic hepatitis and
hepatocyte fragility in association with disruption of hep-
atocyte keratin filaments mouse models [27]. BYSL, to-
gether with keratin 18 are thought to be involved in
teratocarcinoma.
THBS1 encodes a protein that mediates cell-to-cell and
cell-to-matrix interactions and interacts with several pro-
teins including the structural proteins encoded by COL7A1.
THBS1 has been shown to play roles in platelet aggregation,
angiogenesis, and tumorigenesis and linked to auto im-
mune disorders (Sjogren Syndrome). Mutant mice show
abnormal cystic duct morphology, dilated gall bladder, ab-
normal pancreas morphology and pancreas inflammation
[28]. COL7A1 mutations are linked to two skin disorders,
epidermolysis bullosa and keratosis palmoplantaris.
TP53 germline mutations are linked to Li-Fraumeni
syndrome, a rare autosomal dominant disorder that in-
creases the risk of developing several types of cancer,
particularly in children and young adults. SETD8 regu-
lates TP53 and is involved in cell cycle progression and
developmental processes.
No human disorders have been ascribed to the epider-
mal growth factor receptor EPS15. Dynamin (DNM1)
encodes a microtubule-binding protein and been associ-
ated with early infantile epileptic encephalopathy. Little
is known about the remaining complexes.
The identification of a gene with different damaging var-
iants in different individuals (recurrently mutated gene)
also evidences pathogenicity [29]. In total, we identified 13
genes recurrently mutated, forming either PPI or CH and
as well as de novo or in homozygosis. Importantly, the al-
leles of recurrently mutated genes are not necessarily the
same (gene mutated at different sites). Eight of the 13 re-
currently mutated genes are present in different allelic
forms (marked by * in Additional file 1: Table S2).
As to the phenotype caused by these mutated genes in
mice, there are 9 genes (4 with de novo ACAN, CYLD,
PIK3CA, PPP1R15B, and 5 with inherited variants
DCHS1, KRT18, PGR, THBS1, and TP53) whose mouse
mutants display abnormal liver or pancreas (including
abnormal cystic duct and pancreas inflammation among
others; Additional file 1: Table S2).
Gene-based and gene-set-based association test
Gene-based association tests were performed on the genes
carrying rare and damaging variants (refer to Additional
file 1: Figure S2). The p-values appear to be well estimated
(as indicated by a qq-plot; Additional file 1: Figure S1), the
good agreement with null distribution indicates no major
biases due population stratification or technical issues. No
signal reached the significance threshold of <10−6 for
20,000 genes tested although TRIM28 achieved a
significance level of 3.9 × 10−5, suggestive of enrichment in
rare damaging variants (Additional file 1: Table S3).
To boost power for association analysis, we attempted
to account for biological or functional relatedness by
resorting to PPI (STRINGDB) and pathway (MsigDB) da-
tabases to group rare variants for association test. Pathway
enrichment testing yielded no significant results.
Interestingly, PPI analyses revealed that the PPI pair
TRIM28 and ZNF382 were overrepresented in the pa-
tient group when compared to controls (p < =3.60x10−6,
Bonferroni corrected p < =0.042; Table 2). There are 3
individuals carrying rare damaging variants on TRIM28
and 2 individuals with rare damaging variants on
ZNF382 (Additional file 1: Table S1). This indicates the
role of TRIM28 as a putative significant player in CDD.
TRIM28 is known to regulate endoderm differentiation
including liver and pancreas structures during early em-
bryogenesis [30]. Trim28 knockout mice are embryonic
lethal and show abnormal development of the digestive
system and neural tube [31]. Until recently, studies re-
vealed the role of TRIM28 on genomic imprinting dur-
ing embryo development [32], it has provided sights on
its role in the developmental process.
TRIM28 is also listed among 610 SMR genes in cancer.
Searching functional overlap among genes
In order to fully understand how this myriad of mu-
tated genes identified in our patients could contribute
Table 2 Association results for PPI gene-sets
PPI pairs Markers tested Empirical p-value
TRIM28 + ZNF382 13 3.60 × 10−6
TRIM28 + KDM1A 9 1.17 × 10−5
TRIM28 + ZNF274 20 2.93 × 10−5
TRIM28 + HDAC1 9 4.30 × 10−5
TRIM28 + DNMT3A 8 4.35 × 10−5
TRIM28 + RNF4 9 5.61 × 10−5
TRIM28 + SERTAD1 10 6.22 × 10−5
TRIM28 + HTRA2 10 6.23 × 10−5
TRIM28 + TOPORS 8 6.72 × 10−5
IRF1 + TRIM28 8 6.86 × 10−5
TRIM28 + IRF7 9 6.95 × 10−5
TRIM28 + ZNF689 10 8.62 × 10−5
TRIM28 + VEZF1 9 9.40 × 10−5
TRIM28 + UBE2U 8 9.76 × 10−5
TRIM28 + MIS12 12 1.05 × 10−4
RUVBL2 + TRIM28 10 1.26 × 10−4
TRIM28 + TRIM33 10 1.30 × 10−4
TRIM28 + ZNF354A 14 1.57 × 10−4
TRIM28 + SOCS1 9 1.83 × 10−4
Wong et al. BMC Medical Genomics  (2016) 9:75 Page 6 of 10
to the CDD phenotype and to consider whether our
findings fit into any pathological process, we performed
gene/pathway-set enrichment analyses and a careful exam-
ination of the genetic profile or mutational load of each pa-
tient. No enriched geneset was found using DAVID [33].
However, GeneMANIA [34] identified 12 genes being part
of the same network as indicated by their pathway and
physical interactions (Fig. 2). Among these, 5 had de novo
variants and 7 were recurrently mutated (forming CH or
PPIs) at different sites.
Additional file 1: Table S2 presents the genetic profile
of each of the 23 CDD patients with damaging alleles,
the involvement of the mutated gene in other human
disorders and the phenotype displayed by mutant mice.
Several patients had more than one de novo variants
and/or more than one damaging allele advocating the
idea of CDD being an oligogenic and genetically hetero-
geneous disorder and as such, the phenotype will be
variable and result from gene interactions. Hence the
challenge in disentangling such disorders.
Seven patients had no damaging variants (in bold in Add-
itional file 1: Table S1). Among these, patients CC221C and
CC232C had concomitant developmental disorders. Not
finding damaging alleles indicates i) we missed them; ii)
those patients may have small chromosomal anomalies or
copy number variations (CNV) or, (iii) non-genetic disease
cause. Patient CC7, had a de novo frameshift in PPP2R2B,
a gene linked to spinocerebral ataxia, and inherited dam-
aging alleles in the PPI pair THBS1 +COL7A1. Whether
PPP2R2B will eventually confer the spinocerebral ataxia
phenotype (late onset) to that patient and the CDD is
caused by the variants in PPI is not known. The patient is
being monitored.
Discussion
The two current theories for the aetiology of CDD,
“obstructing segment” hypothesis and the “pancreatic reflux”
hypothesis are not mutually exclusive. Both imply that CDD
results from a failure in the hepatobiliary-pancreatic devel-
opment. Given the multitude of molecular and cellular
events that take place during the development of the hepa-
tobiliary system, it is conceivable that DNA alterations in
genes governing such processes could underlie CDD. As the
number of interacting molecules during development is
large, CDD may result from the accumulation of mutations
in several genes. Variants in different genes of related path-
ways may lead to the same disorder, the same gene may
have different severe variants in unrelated patients or, a
given variant may lead to different clinical manifestations in
different individuals. Hence, the marked genetic heterogen-
eity that characterizes human diseases [35, 36].
The genetic profile of these CDD patients indicates the
disorder is not only genetically heterogeneous but also oli-
gogenic, comprising di-genic models, and is consistent
with the sporadic presentation of the disease and the scar-
city of familial cases. Although some of the genes with de
novo pathogenic mutations appear to be functionally or
biologically linked with developmental processes of the
hepatobiliary tract, it would appear that CDD obeys a
“two or multi-hit hypotheses” where the effect of de novo
variants may be “enhanced” by the presence of damaging
alleles of genes other than those with the de novo variant.
These damaging alleles may form compound heterozy-
gotes and/or be PPI-related. As CDD is more common in
Asians, the frequencies of alleles conferring risk to the dis-
order in that population are likely to be higher than in
other ethnicities. The presence of an underlying genetic
Fig. 2 Biological network integration of genes by GeneMania. All genes with variants were submitted for functional network analyses. Twelve
interlinked genes were identified. Five with de novo variants (MAP2K1, PIK3CA, TLN1, PPP2R2B, SDC3) and 7 recurrently mutated (BYSL, EPS15,
DNM1, COL7A1, THBS1, TP53, SETD8)
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risk factor seems to be corroborated by our gene-
enrichment test whereby we evaluated the contribution of
rare damaging variants by a gene-based case–control asso-
ciation analysis [36]. These rare variants could modify the
manifestation of the disease by enhancing or reducing the
effect of other co-existing alleles and provide the extra
stimulus that drives those susceptible individuals to dis-
ease. Thus, it would appear that carriers of TRIM28 or
ZNF382 rare damaging variants might have a higher risk
of developing CDD. Replication of this finding in inde-
pendent Chinese patients is needed. Similar studies should
be conducted in non-Asian CDD patients to assess
whether the TRIM28 association is population specific.
Interestingly, multiple CDD genes coincided with SMR
cancer genes as suggested by the enrichment of SMR
genes with de novo variants and the existence of our top
associated gene-pair (TRIM28-ZNF382) among the SMR
list in our CDD samples. Our data is in line with the
established link between cholangiocarcinoma and CDD.
Importantly, our literature review showed that CDD is
not only linked to cholangiocarcinoma but also to other
types of malignancies, including adenocarcinomas, pri-
mary squamous carcinoma of the liver, benign squamous
metaplasia and adenosquamous carcinoma [37–39].
We then investigated if of those genes with damaging
variants (either de novo or inherited) were biologically
and/or functionally related and the phenotypes that
these genes originate, when mutated, in human and
mice. Twelve genes with damaging alleles were found to
physically or functionally interact (Fig. 2). As for the
phenotypic effect in human or mice, 6 genes carrying de
novo have been associated with human developmental
disorders that involve overgrowth of the epithelial and/
or connective tissues, bone morphologies (Additional file
1: Table S2). Those genes not reported implicated in hu-
man disorders (N = 15) are all involved in cell-to-cell
and cell-to-matrix interactions and in maintaining the
structural integrity of the epithelial cells.
Except for one patient with Noonan’s syndrome, none
of the patients displayed any phenotype other than CDD
at the time of diagnosis. We can only speculate that, al-
legedly, unrelated disorders may also be genetically con-
nected as indicated by the human disease network map
(or diseasome) [40, 41].
The excess of damaging alleles in genes mainly in-
volved in soft tissues disorders and conditions related to
overgrowth of tissues (benign or cancerogenous) is in
line with i) the clinical observation regarding the higher
incidence of cholangiocarcinomas among CDD patients;
ii) the notion that CDD is caused by tissue overgrowth
which would fit with the “obstructing segment” and the
“pancreatic reflux” hypotheses on the CDD aetiology.
Moreover, the cholangiocyte function is likely to be af-
fected and so, the bile composition which in turn may
cause further damage to the epithelium. These hypoth-
eses are not mutually exclusive. Either stenosis or
pancreatico-biliary junction defect can underlie CDD
and which of them triggers the disease would depend on
the genetic background of the patient.
Despite the array of databases and prediction tools avail-
able, very little is known about the intricate ways in which
genes interact, the development of the hepato-biliary
structures, or the function of many genes. For example,
one de novo and two inherited damaging alleles in an evo-
lutionarily constrained gene, TXLNB, were identified in
two patients. Yet, very little is known about this gene.
However, finding genes with rare damaging variants at dif-
ferent sites in different individuals (gene recurrently mu-
tated) can be used as a “pathogenicity criteria” to ascribe
the involvement of a gene in a disorder [42]. For rare, gen-
etically heterogeneous diseases such as CDD, the involve-
ment of a mutated gene in the disease may only be
consolidated by the identification of new or recurrent mu-
tations of the same gene in independent patients.
Ours is the first genetic study ever conducted on CDD
patients. The study is not without limitations, small
sample size being the most obvious. Yet, genes function-
ally linked and recurrently mutated have been identified
providing a glimpse into the genetic factors that may be
underlying CDD. For such a rare and genetically hetero-
geneous disorder, replication of our findings implies un-
attainable sample size. Also, our data indicates that the
phenotype results from interactions between more of
one mutated gene (digenic/oligogenic) which hampers
the possibility of a clean functional study.
Conclusions
Our data supports a strong genetic basis for CDD and
show that CDD is not only genetically heterogeneous but
also non-monogenic, requiring mutations in more than
one genes for the disease to develop. The data is consist-
ent with the rarity and sporadic presentation of CDD.
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